TY - JOUR AU - Ferlay, J. AU - Soerjomataram, I. AU - Dikshit, R. AU - Eser, S. AU - Mathers, C. AU - Rebelo, M. PY - 2015 DA - 2015// TI - Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 JO - Int J Cancer VL - 136 UR - https://doi.org/10.1002/ijc.29210 DO - 10.1002/ijc.29210 ID - Ferlay2015 ER - TY - JOUR AU - Wartko, P. AU - Sherman, M. E. AU - Yang, H. P. AU - Felix, A. S. AU - Brinton, L. A. AU - Trabert, B. PY - 2013 DA - 2013// TI - Recent changes in endometrial cancer trends among menopausal-age US women JO - Cancer Epidemiol VL - 37 UR - https://doi.org/10.1016/j.canep.2013.03.008 DO - 10.1016/j.canep.2013.03.008 ID - Wartko2013 ER - TY - JOUR AU - Creasman, W. T. AU - Odicino, F. AU - Maisonneuve, P. AU - Quinn, M. A. AU - Beller, U. AU - Benedet, J. L. PY - 2006 DA - 2006// TI - Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer JO - Int J Gynaecol Obstet VL - 95 UR - https://doi.org/10.1016/S0020-7292(06)60031-3 DO - 10.1016/S0020-7292(06)60031-3 ID - Creasman2006 ER - TY - JOUR AU - Kong, A. AU - Johnson, N. AU - Kitchener, H. C. AU - Lawrie, T. A. PY - 2012 DA - 2012// TI - Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis JO - J Natl Cancer Inst VL - 104 UR - https://doi.org/10.1093/jnci/djs374 DO - 10.1093/jnci/djs374 ID - Kong2012 ER - TY - JOUR AU - Stelloo, E. AU - Nout, R. A. AU - Osse, E. M. AU - Jurgenliemk-Schulz, I. J. AU - Jobsen, J. J. AU - Lutgens, L. C. PY - 2016 DA - 2016// TI - Improved risk assessment by integrating molecular and Clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2878 DO - 10.1158/1078-0432.CCR-15-2878 ID - Stelloo2016 ER - TY - JOUR AU - Murali, R. AU - Soslow, R. A. AU - Weigelt, B. PY - 2014 DA - 2014// TI - Classification of endometrial carcinoma: more than two types JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70591-6 DO - 10.1016/S1470-2045(13)70591-6 ID - Murali2014 ER - TY - JOUR AU - Li, J. AU - Yen, C. AU - Liaw, D. AU - Podsypanina, K. AU - Bose, S. AU - Wang, S. I. PY - 1997 DA - 1997// TI - PTEN, a putative protein tyrosine Phosphatase gene mutated in human brain, breast, and prostate cancer JO - Science VL - 275 UR - https://doi.org/10.1126/science.275.5308.1943 DO - 10.1126/science.275.5308.1943 ID - Li1997 ER - TY - JOUR AU - Steck, P. A. AU - Pershouse, M. A. AU - Jasser, S. A. AU - Yung, W. K. A. AU - Lin, H. AU - Ligon, A. H. PY - 1997 DA - 1997// TI - Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 That is mutated in multiple advanced cancers JO - Nat Genet VL - 15 UR - https://doi.org/10.1038/ng0497-356 DO - 10.1038/ng0497-356 ID - Steck1997 ER - TY - JOUR AU - Xu, W. AU - Yang, Z. AU - Zhou, S. -. F. AU - Lu, N. PY - 2014 DA - 2014// TI - Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors JO - Drug Des Devel Ther VL - 8 UR - https://doi.org/10.2147/DDDT.S71061 DO - 10.2147/DDDT.S71061 ID - Xu2014 ER - TY - JOUR AU - Waite, K. A. AU - Eng, C. PY - 2002 DA - 2002// TI - Protean PTEN: form and function JO - Am J Hum Genet VL - 70 UR - https://doi.org/10.1086/340026 DO - 10.1086/340026 ID - Waite2002 ER - TY - JOUR AU - McConechy, M. K. AU - Ding, J. AU - Cheang, M. C. U. AU - Wiegand, K. AU - Senz, J. AU - Tone, A. PY - 2012 DA - 2012// TI - Use of mutation profiles to refine the classification of endometrial carcinomas JO - J Pathol VL - 228 ID - McConechy2012 ER - TY - STD TI - Akiyama-Abe A, Minaguchi T, Nakamura Y, Michikami H, Shikama A, Nakao S et al. Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas. Br J Cancer. 2013;109(6):1703-10. doi:10.1038/bjc.2013.455. ID - ref12 ER - TY - JOUR AU - Kumar, A. AU - Fernandez-Capetillo, O. AU - Carrera, A. C. PY - 2010 DA - 2010// TI - Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0914242107 DO - 10.1073/pnas.0914242107 ID - Kumar2010 ER - TY - JOUR AU - Ibrahim, Y. H. AU - Garcia-Garcia, C. AU - Serra, V. AU - He, L. AU - Torres-Lockhart, K. AU - Prat, A. PY - 2012 DA - 2012// TI - PI3K Inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition JO - Cancer discovery. VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-11-0348 DO - 10.1158/2159-8290.CD-11-0348 ID - Ibrahim2012 ER - TY - JOUR AU - Satoh, M. S. AU - Lindahl, T. PY - 1992 DA - 1992// TI - Role of poly(ADP-ribose) formation in DNA repair JO - Nature VL - 356 UR - https://doi.org/10.1038/356356a0 DO - 10.1038/356356a0 ID - Satoh1992 ER - TY - JOUR AU - Farmer, H. AU - McCabe, N. AU - Lord, C. J. AU - Tutt, A. N. AU - Johnson, D. A. AU - Richardson, T. B. PY - 2005 DA - 2005// TI - Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy JO - Nature VL - 434 UR - https://doi.org/10.1038/nature03445 DO - 10.1038/nature03445 ID - Farmer2005 ER - TY - JOUR AU - Bryant, H. E. AU - Schultz, N. AU - Thomas, H. D. AU - Parker, K. M. AU - Flower, D. AU - Lopez, E. PY - 2005 DA - 2005// TI - Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase JO - Nature VL - 434 UR - https://doi.org/10.1038/nature03443 DO - 10.1038/nature03443 ID - Bryant2005 ER - TY - JOUR AU - Audeh, M. W. AU - Carmichael, J. AU - Penson, R. T. AU - Friedlander, M. AU - Powell, B. AU - Bell-McGuinn, K. M. PY - 2010 DA - 2010// TI - Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial JO - Lancet VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)60893-8 DO - 10.1016/S0140-6736(10)60893-8 ID - Audeh2010 ER - TY - JOUR AU - Gelmon, K. A. AU - Tischkowitz, M. AU - Mackay, H. AU - Swenerton, K. AU - Robidoux, A. AU - Tonkin, K. PY - 2011 DA - 2011// TI - Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70214-5 DO - 10.1016/S1470-2045(11)70214-5 ID - Gelmon2011 ER - TY - JOUR AU - Amin, O. AU - Beauchamp, M. C. AU - Nader, P. A. AU - Laskov, I. AU - Iqbal, S. AU - Philip, C. A. PY - 2015 DA - 2015// TI - Suppression of homologous recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors JO - BMC Cancer VL - 15 UR - https://doi.org/10.1186/s12885-015-1803-y DO - 10.1186/s12885-015-1803-y ID - Amin2015 ER - TY - JOUR AU - Koppensteiner, R. AU - Samartzis, E. P. AU - Noske, A. AU - Teichman, A. AU - Dedes, I. AU - Gwerder, M. PY - 2014 DA - 2014// TI - Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0100041 DO - 10.1371/journal.pone.0100041 ID - Koppensteiner2014 ER - TY - JOUR AU - Shen, Y. AU - Rehman, F. L. AU - Feng, Y. AU - Boshuizen, J. AU - Bajrami, I. AU - Elliott, R. PY - 2013 DA - 2013// TI - BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency JO - Clinical Cancer Res. VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-1391 DO - 10.1158/1078-0432.CCR-13-1391 ID - Shen2013 ER - TY - JOUR AU - Alvarez, R. D. AU - Matulonis, U. A. AU - Herzog, T. J. AU - Coleman, R. L. AU - Monk, B. J. AU - Markman, M. PY - 2016 DA - 2016// TI - Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer JO - Gynecol Oncol VL - 141 UR - https://doi.org/10.1016/j.ygyno.2016.03.005 DO - 10.1016/j.ygyno.2016.03.005 ID - Alvarez2016 ER - TY - JOUR AU - Mendes-Pereira, A. M. AU - Martin, S. A. AU - Brough, R. AU - McCarthy, A. AU - Taylor, J. R. AU - Kim, J. S. PY - 2009 DA - 2009// TI - Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors JO - EMBO Mol Med VL - 1 UR - https://doi.org/10.1002/emmm.200900041 DO - 10.1002/emmm.200900041 ID - Mendes-Pereira2009 ER - TY - JOUR AU - Gonzalez-Billalabeitia, E. AU - Seitzer, N. AU - Song, S. J. AU - Song, M. S. AU - Patnaik, A. AU - Liu, X. S. PY - 2014 DA - 2014// TI - Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition JO - Cancer discovery. VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-13-0230 DO - 10.1158/2159-8290.CD-13-0230 ID - Gonzalez-Billalabeitia2014 ER - TY - JOUR AU - Chatterjee, P. AU - Choudhary, G. S. AU - Sharma, A. AU - Singh, K. AU - Heston, W. D. AU - Ciezki, J. PY - 2013 DA - 2013// TI - PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0060408 DO - 10.1371/journal.pone.0060408 ID - Chatterjee2013 ER - TY - JOUR AU - McEllin, B. AU - Camacho, C. V. AU - Mukherjee, B. AU - Hahm, B. AU - Tomimatsu, N. AU - Bachoo, R. M. PY - 2010 DA - 2010// TI - PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-4295 DO - 10.1158/0008-5472.CAN-09-4295 ID - McEllin2010 ER - TY - JOUR AU - Minami, D. AU - Takigawa, N. AU - Takeda, H. AU - Takata, M. AU - Ochi, N. AU - Ichihara, E. PY - 2013 DA - 2013// TI - Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells JO - Mol Cancer Res VL - 11 UR - https://doi.org/10.1158/1541-7786.MCR-12-0401 DO - 10.1158/1541-7786.MCR-12-0401 ID - Minami2013 ER - TY - JOUR AU - Dedes, K. J. AU - Wetterskog, D. AU - Mendes-Pereira, A. M. AU - Natrajan, R. AU - Lambros, M. B. AU - Geyer, F. C. PY - 2010 DA - 2010// TI - PTEN deficiency in Endometrioid endometrial Adenocarcinomas predicts sensitivity to PARP inhibitors JO - Sci Transl Med VL - 2 UR - https://doi.org/10.1126/scitranslmed.3001538 DO - 10.1126/scitranslmed.3001538 ID - Dedes2010 ER - TY - JOUR AU - Forster, M. D. AU - Dedes, K. J. AU - Sandhu, S. AU - Frentzas, S. AU - Kristeleit, R. AU - Ashworth, A. PY - 2011 DA - 2011// TI - Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer JO - Nat Rev Clin Oncol VL - 8 UR - https://doi.org/10.1038/nrclinonc.2011.42 DO - 10.1038/nrclinonc.2011.42 ID - Forster2011 ER - TY - STD TI - Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets. 2014;15(1):65–79. ID - ref31 ER - TY - JOUR AU - Maira, S. M. AU - Pecchi, S. AU - Huang, A. AU - Burger, M. AU - Knapp, M. AU - Sterker, D. PY - 2012 DA - 2012// TI - Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor JO - Mol Cancer Ther VL - 11 UR - https://doi.org/10.1158/1535-7163.MCT-11-0474 DO - 10.1158/1535-7163.MCT-11-0474 ID - Maira2012 ER - TY - JOUR AU - Bendell, J. C. AU - Rodon, J. AU - Burris, H. A. AU - Jonge, M. AU - Verweij, J. AU - Birle, D. PY - 2012 DA - 2012// TI - Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.36.1360 DO - 10.1200/JCO.2011.36.1360 ID - Bendell2012 ER - TY - JOUR AU - Vansteenkiste, J. F. AU - Canon, J. L. AU - Braud, F. D. AU - Grossi, F. AU - Pas, T. AU - Gray, J. E. PY - 2015 DA - 2015// TI - Safety and efficacy of Buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000607 DO - 10.1097/JTO.0000000000000607 ID - Vansteenkiste2015 ER - TY - JOUR AU - Hyman, D. M. AU - Snyder, A. E. AU - Carvajal, R. D. AU - Gerecitano, J. F. AU - Voss, M. H. AU - Ho, A. L. PY - 2015 DA - 2015// TI - Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors JO - Cancer Chemother Pharmacol VL - 75 UR - https://doi.org/10.1007/s00280-015-2693-z DO - 10.1007/s00280-015-2693-z ID - Hyman2015 ER - TY - JOUR AU - Bedard, P. L. AU - Tabernero, J. AU - Janku, F. AU - Wainberg, Z. A. AU - Paz-Ares, L. AU - Vansteenkiste, J. PY - 2015 DA - 2015// TI - A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-1814 DO - 10.1158/1078-0432.CCR-14-1814 ID - Bedard2015 ER - TY - JOUR AU - Bradford, L. S. AU - Rauh-Hain, A. AU - Clark, R. M. AU - Groeneweg, J. W. AU - Zhang, L. AU - Borger, D. PY - 2014 DA - 2014// TI - Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer JO - Gynecol Oncol VL - 133 UR - https://doi.org/10.1016/j.ygyno.2014.02.022 DO - 10.1016/j.ygyno.2014.02.022 ID - Bradford2014 ER - TY - JOUR AU - Kuramoto, H. AU - Tamura, S. AU - Notake, Y. PY - 1972 DA - 1972// TI - Establishment of a cell line of human endometrial adenocarcinoma in vitro JO - Am J Obstet Gynecol VL - 114 UR - https://doi.org/10.1016/0002-9378(72)90861-7 DO - 10.1016/0002-9378(72)90861-7 ID - Kuramoto1972 ER - TY - JOUR AU - Xiong, S. AU - Klausen, C. AU - Cheng, J. C. AU - Leung, P. C. PY - 2016 DA - 2016// TI - Activin B promotes endometrial cancer cell migration by down-regulating E-cadherin via SMAD-independent MEK-ERK1/2-SNAIL signaling JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.9483 DO - 10.18632/oncotarget.9483 ID - Xiong2016 ER - TY - JOUR AU - Albitar, L. AU - Pickett, G. AU - Morgan, M. AU - Davies, S. AU - Leslie, K. K. PY - 2007 DA - 2007// TI - Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells JO - Gynecol Oncol VL - 106 UR - https://doi.org/10.1016/j.ygyno.2007.02.033 DO - 10.1016/j.ygyno.2007.02.033 ID - Albitar2007 ER - TY - JOUR AU - Chen, S. AU - Sun, K. X. AU - Liu, B. L. AU - Zong, Z. H. AU - Zhao, Y. PY - 2016 DA - 2016// TI - MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-alpha JO - Mol Cancer VL - 15 UR - https://doi.org/10.1186/s12943-016-0496-4 DO - 10.1186/s12943-016-0496-4 ID - Chen2016 ER - TY - JOUR AU - Nishida, M. AU - Kasahara, K. AU - Kaneko, M. AU - Iwasaki, H. AU - Hayashi, K. PY - 1985 DA - 1985// TI - Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors JO - Nihon Sanka Fujinka Gakkai zasshi VL - 37 ID - Nishida1985 ER - TY - JOUR AU - Miyasaka, A. AU - Oda, K. AU - Ikeda, Y. AU - Wada-Hiraike, O. AU - Kashiyama, T. AU - Enomoto, A. PY - 2014 DA - 2014// TI - Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-179 DO - 10.1186/1471-2407-14-179 ID - Miyasaka2014 ER - TY - JOUR AU - Oda, K. AU - Stokoe, D. AU - Taketani, Y. AU - McCormick, F. PY - 2005 DA - 2005// TI - High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-05-2620 DO - 10.1158/0008-5472.CAN-05-2620 ID - Oda2005 ER - TY - JOUR AU - Dawe, C. J. AU - Banfield, W. G. AU - Morgan, W. D. AU - Slatick, M. S. AU - Curth, H. O. PY - 1964 DA - 1964// TI - Growth in continuos culture, and in hamsters, of cells from a neoplasm associated with Acanthosis Nigricans JO - J Natl Cancer Inst VL - 33 ID - Dawe1964 ER - TY - JOUR AU - Chiappinelli, K. B. AU - Haynes, B. C. AU - Brent, M. R. AU - Goodfellow, P. J. PY - 2012 DA - 2012// TI - Reduced DICER1 elicits an interferon response in endometrial cancer cells JO - Mol Cancer Res VL - 10 UR - https://doi.org/10.1158/1541-7786.MCR-11-0520 DO - 10.1158/1541-7786.MCR-11-0520 ID - Chiappinelli2012 ER - TY - JOUR AU - Korch, C. AU - Spillman, M. A. AU - Jackson, T. A. AU - Jacobsen, B. M. AU - Murphy, S. K. AU - Lessey, B. A. PY - 2012 DA - 2012// TI - DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination JO - Gynecol Oncol VL - 127 UR - https://doi.org/10.1016/j.ygyno.2012.06.017 DO - 10.1016/j.ygyno.2012.06.017 ID - Korch2012 ER - TY - STD TI - Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013;19(13):3533–44. doi:10.1158/1078-0432.CCR-12-3815. ID - ref48 ER - TY - JOUR AU - Fong, P. C. AU - Boss, D. S. AU - Yap, T. A. AU - Tutt, A. AU - Wu, P. AU - Mergui-Roelvink, M. PY - 2009 DA - 2009// TI - Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers JO - N Engl J Med VL - 361 UR - https://doi.org/10.1056/NEJMoa0900212 DO - 10.1056/NEJMoa0900212 ID - Fong2009 ER - TY - JOUR AU - Ando, Y. AU - Inada-Inoue, M. AU - Mitsuma, A. AU - Yoshino, T. AU - Ohtsu, A. AU - Suenaga, N. PY - 2014 DA - 2014// TI - Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors JO - Cancer Sci VL - 105 UR - https://doi.org/10.1111/cas.12350 DO - 10.1111/cas.12350 ID - Ando2014 ER - TY - JOUR AU - Franken, N. A. AU - Rodermond, H. M. AU - Stap, J. AU - Haveman, J. AU - Bree, C. PY - 2006 DA - 2006// TI - Clonogenic assay of cells in vitro JO - Nat Protoc VL - 1 UR - https://doi.org/10.1038/nprot.2006.339 DO - 10.1038/nprot.2006.339 ID - Franken2006 ER - TY - JOUR AU - Maor, S. AU - Papa, M. Z. AU - Yarden, R. I. AU - Friedman, E. AU - Lerenthal, Y. AU - Lee, S. W. PY - 2007 DA - 2007// TI - Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1 JO - Horm Metab Res VL - 39 UR - https://doi.org/10.1055/s-2007-970415 DO - 10.1055/s-2007-970415 ID - Maor2007 ER - TY - JOUR AU - Laskov, I. AU - Abou-Nader, P. AU - Amin, O. AU - Philip, C. A. AU - Beauchamp, M. C. AU - Yasmeen, A. PY - 2016 DA - 2016// TI - Metformin increases E-cadherin in tumors of diabetic patients with endometrial cancer and suppresses epithelial-Mesenchymal transition in endometrial cancer cell lines JO - Int J Gynecol Cancer VL - 26 UR - https://doi.org/10.1097/IGC.0000000000000761 DO - 10.1097/IGC.0000000000000761 ID - Laskov2016 ER - TY - STD TI - Xiong S, Cheng JC, Klausen C, Zhao J, Leung PC. TGF-beta1 stimulates migration of type II endometrial cancer cells by down-regulating PTEN via activation of SMAD and ERK1/2 signaling pathways. Oncotarget. 2016;7(38):61262–72. doi:10.18632/oncotarget.11311. ID - ref54 ER - TY - STD TI - Tsikouras P, Bouchlariotou S, Vrachnis N, Dafopoulos A, Galazios G, Csorba R et al. Endometrial cancer: molecular and therapeutic aspects. Eur J Obstet Gynecol Reprod Biol. 2013;169(1):1–9. doi:10.1016/j.ejogrb.2013.01.018. ID - ref55 ER - TY - JOUR AU - Hers, I. AU - Vincent, E. E. AU - Tavaré, J. M. PY - 2011 DA - 2011// TI - Akt signalling in health and disease JO - Cell Signal VL - 23 UR - https://doi.org/10.1016/j.cellsig.2011.05.004 DO - 10.1016/j.cellsig.2011.05.004 ID - Hers2011 ER - TY - JOUR AU - Laskov, I. AU - Drudi, L. AU - Beauchamp, M. C. AU - Yasmeen, A. AU - Ferenczy, A. AU - Pollak, M. PY - 2014 DA - 2014// TI - Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer JO - Gynecol Oncol VL - 134 UR - https://doi.org/10.1016/j.ygyno.2014.06.014 DO - 10.1016/j.ygyno.2014.06.014 ID - Laskov2014 ER - TY - JOUR AU - Janzen, D. M. AU - Paik, D. Y. AU - Rosales, M. A. AU - Yep, B. AU - Cheng, D. AU - Witte, O. N. PY - 2013 DA - 2013// TI - Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo JO - Mol Cancer Ther VL - 12 UR - https://doi.org/10.1158/1535-7163.MCT-13-0572 DO - 10.1158/1535-7163.MCT-13-0572 ID - Janzen2013 ER - TY - JOUR AU - Juvekar, A. AU - Burga, L. N. AU - Hu, H. AU - Lunsford, E. P. AU - Ibrahim, Y. H. AU - Balmana, J. PY - 2012 DA - 2012// TI - Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer JO - Cancer discovery VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-11-0336 DO - 10.1158/2159-8290.CD-11-0336 ID - Juvekar2012 ER - TY - JOUR AU - Cardnell, R. J. AU - Feng, Y. AU - Diao, L. AU - Fan, Y. H. AU - Masrorpour, F. AU - Wang, J. PY - 2013 DA - 2013// TI - Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-1975 DO - 10.1158/1078-0432.CCR-13-1975 ID - Cardnell2013 ER - TY - JOUR AU - De, P. AU - Sun, Y. AU - Carlson, J. H. AU - Friedman, L. S. AU - Leyland-Jones, B. R. AU - Dey, N. PY - 2014 DA - 2014// TI - Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness JO - Neoplasia VL - 16 UR - https://doi.org/10.1593/neo.131694 DO - 10.1593/neo.131694 ID - De2014 ER -